Company intelligence / Profile preview

InVixa

San Jose, California, United States

Ownership: Private
Development stage: Other

Overview

InVixa is developing inhaled statin therapies targeting COVID-19 pneumonia and ARDS; as of 2021, the program is preclinical and partnered with University of California, Davis for technology licensing. No clinical data publicly reported yet.

Therapeutic areas: Infectious DiseasesPulmonology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Invixia

Preclinical

Partnerships

University of California, Davis

Beyond the preview

Go deeper on InVixa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InVixa.

Explore the full profile